

---

## KYA1797K

产品编号: D50972

CAS: 1956356-56-1

分子式: C<sub>17</sub>H<sub>11</sub>KN<sub>2</sub>O<sub>6</sub>S<sub>2</sub>

纯度: ≥98%

InChi: InChI=1S/C<sub>17</sub>H<sub>12</sub>N<sub>2</sub>O<sub>6</sub>S<sub>2</sub>.K/c20-15(21)7-8-18-16(22)14(27-17(18)26)9-12-5-6-13(25-12)10-1-3-11(4-2-10)19(23)24;/h1-6,9H,7-8H<sub>2</sub>, (H,20,21);/q;+1/p-1/b14-9-;

InChi Key: PHUNRLYHXGMOLG-WQRRWHLMSA-M

Smiles: [K+].[O-]C(=O)CCN1C(=O)/C(=C/C2=CC=C(O2)C2C=CC(=CC=2)[N+](O)=O)/SC1=S

外观: 固体粉末

作用通路: Wnt

溶解性: DMSO up to 100 mM

保存条件: Store in dry, dark place for one year.

产品介绍: KYA1797K is a highly potent and selective Wnt/ $\beta$ -catenin inhibitor with IC<sub>50</sub> ~0.75  $\mu$ M (TOPflash assay). It binds directly to the regulators of G-protein signaling domain of axin, initiating  $\beta$ -catenin and Ras degradation through enhancement of the  $\beta$ -catenin destruction complex activating GSK3 $\beta$ . KYA1797K can effectively suppress the growth of CRCs harboring APC and KRAS mutations, as shown by various in vitro studies and by in vivo studies using xenograft and transgenic mouse models of tumors induced by APC and KRAS mutations. Destabilization of both  $\beta$ -catenin and Ras via targeting axin is a potential therapeutic strategy for treatment of CRC and other type cancers activated Wnt/ $\beta$ -catenin and Ras pathways.